Rana McKay joins Alicia Morgans to discuss the outcomes of a study investigating randomized patients with high-risk prostate cancer (Gleason ≥4+3, PSA >20, T3 disease, and lymph nodes <20 mm) to either abiraterone + prednisone + apalutamide + leuprolide (APAL) or abiraterone + prednisone + leuprolide (APL) for a total of 6 cycles (each cycle 28 days), followed by radical prostatectomy. A total...
urology, endourology, endourology mentorship, urology mentorship, Endourological Society’s accreditation, Endourological Society-accredited urology fellowship programs, future of urological care and research.
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies:…
bladder cancer, Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma, Atezolizumab, IMvigor130 trial, metastatic urothelial carcinoma (mUC), PD-L1 expression, CheckMate 901…
bladder cancer (BC), neoadjuvant chemotherapy after radical cystectomy (RC), gemcitabine/cisplatin, MVAC/dose-dense MVAC, gemcitabine/carboplatin, circulating tumor DNA.
prostate cancer, Prostate specific membrane antigen (PSMA), positron emission tomography (PET), PSMA PET, PSMA-radioguided surgery (PSMA-RGS), PSMA-Radioguided Surgery in Recurrent Prostate Cancer, Robot-Assisted and Open…
Genetic alterations in fibroblast growth factor receptors (FGFRs), urothelial carcinoma, FGFR3 or FGFR2 genetic alterations, non-muscle invasive bladder cancer (NMIBC), muscle-invasive bladder cancer (MIBC).
prostate cancer, grade group 2 prostate cancer, ProtecT trial, International Society of Urological Pathologists (ISUP), ISUP grading system, radical prostatectomy, low-grade prostate cancer.
Alicia Morgans speaks with Louise Emmett about the ENZA-p study, presented at ESMO 2023. This groundbreaking research explores the combination of lutetium and enzalutamide in…
Andrea Miyahira hosts Ping Mu to discuss his group’s research on prostate cancer resistance to anti-androgens. Dr. Mu’s study, published in Oncogene, focuses on the…
Ashish Kamat converses with Akshay Sood about the challenging diagnosis and management of non-metastatic plasmacytoid bladder cancer. Dr. Sood elaborates on his comprehensive study published…
